Psoriasis is a chronic inflammatory disease affecting approximately 2% of the world’s population. The Psoriasis Knowledge Centre provides dermatologists, family medicine doctors and other healthcare professionals with relevant information including epidemiology, pathophysiology, diagnosis and more.
A treatment section reviews the established treatments available for psoriasis and considers their modes of action, available clinical data and place in the therapeutic pathway.
Also located within the Psoriasis Knowledge Centre is a dedicated educational section focusing on IL-17A in Psoriasis. This free resource is intended to provide healthcare professionals with information on the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A.
This educational resource has been developed for healthcare professionals in Europe who are involved in the care of patients with asthma.
Disease Awareness - This section provides background information regarding the impact of symptomatic asthma and potential management strategies.
RCGP-accredited CME - Within the continuing medical education (CME) activity, you can learn about physician perspectives on managing symptomatic asthma in practice. Richard Russell and Thys van der Molen discuss in four sessions:
What is asthma control: Who, why and how many?
Improving asthma control in the community
Current standard asthma treatment
Pros and cons of additional add-on treatment.
One hour towards your CPD will be rewarded upon successful completion of the evaluation questionnaire
SPIRIVA® Respimat® is approved for use in asthma in the European Union, Japan, USA and many other countries. The indication varies by country and the educational resource may contain information about medications for which indications may not be approved in your country.
The Chronic Spontaneous Urticaria (CSU) Knowledge Centre has been developed to address the current lack of early diagnosis of this condition. Urticaria is more common than previously thought and studies suggest chronic urticaria affects up to 1% of the population at any given time with CSU responsible for two-thirds of these cases.
Allergists, immunologists, dermatologists and other healthcare professionals involved in the management of CSU will find a range of content to support you in effectively diagnosing and treating the condition.
In this resource, you will find a disease overview, symposia highlights platform, video channel and additional resources including an events calendar and useful external links.
Recent additions to this resource are faculty video presentations from the Novartis-sponsored CSU symposium at WCD 2015 and expert slides discussing real-life patient case studies. The case studies explore how treatment recommendations in the recent best-practice guidelines can be applied in the dermatology clinic.
Located within the Psoriasis Knowledge Centre, IL-17A in Psoriasis has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A.
Content is arranged within multiple sections that are easy to navigate. Users can find expert videos, clinical slide decks on topics such as disease pathophysiology and emerging therapies, congress highlights, key publications and links to useful resources.
This free resource is intended for healthcare professionals involved in the treatment and management of patients with psoriasis.
This resource has been developed in collaboration with Novartis Pharma AG.
Respiratory Medicine & Allergy: Vasculitis/Rare Diseases
Elizabeth Hadley,Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK Richard Leach,Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Case History 41-year-old Asian salesman presented following an episode of haemoptysis in which he expectorated a teaspoonful of fresh blood. For several weeks he had been experiencing influenza-like symptoms with lethargy, low-grade fever, arthralgia, breathlessness on climbing stairs and weight loss.
The 2003 British Thoracic Society and Scottish Intercollegiate Guidelines Network asthma management guidelines use the international consensus definition to describe asthma as:
“a chronic inflammatory disorder of the airways. In susceptible individuals inflammatory symptoms are usually associated with widespread but variable airflow obstruction and an increase in airway response to a variety of stimuli. Obstruction is often reversible either spontaneously or with treatment”.
During an asthma attack, also called an asthma exacerbation, airways become swollen and inflamed. The muscles around the airways contract narrowing the bronchial tubes.
Asthma attacks can be minor which improve with home treatment, or severe which can become a life threatening emergency.
This post discusses clinical assessment and treatment of patients with acute asthma exacerbations.
Sun 15 Nov 2015 -
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
INTRODUCTION: This 28-week, phase IIIb study assessed safety and maintenance of response to certolizumab pegol (CZP) in a diverse population of rheumatoid arthritis (RA) patients, stratified by ...
Chronic lymphocytic leukaemia is the most common leukaemia in the Western world and generally..
... affects older populations. These updated ESMO Clinical Practice Guidelines present the latest information on CLL including the diagnosis and molecular biology of CLL and treatment strategies for early and advanced disease.
Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of..
... non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommendations for screening and diagnosis, staging and risk assessment and stage-matched therapeutic strategies including specific recommendations for young and elderly, low-to-high risk subgroups.
After completing this module you should be able to: make a clinical diagnosis of myasthenia gravis, select appropriate diagnostic tests to confirm your diagnosis, and understand the principles of therapy...
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in patients with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have ...